PURPOSE: @entity11044 following a @entity3142 procedure occurs in 5 to 20% of @entity1 . We examine the success of transvaginal urethrolysis in resolving @entity409 . MATERIALS AND METHODS: A retrospective chart review was performed on 39 @entity1 who had undergone transvaginal urethrolysis for @entity11044 following an anti- @entity322 procedure. Preoperatively, a history was taken, and pelvic examination and either video urodynamics or cystoscopy were done. RESULTS: All 39 @entity1 complained of urge @entity322 , 13% had urinary retention, 51% had @entity1494 and 36% voided to completion but had irritative voiding symptoms. Previous surgery included retropubic urethropexy in 41% of the cases, pubovaginal sling in 38% and bladder neck suspension in 21%. Mean length of followup after urethrolysis was 16 months. Of the 39 @entity1 33 (85%) had resolution of urge @entity322 but 5 still required occasional intermittent catheterization. The remaining 6 @entity1 had continued urge @entity322 . An augmentation procedure was performed in 4 @entity1 with improvement of symptoms. CONCLUSIONS: Our data support transvaginal urethrolysis for the treatment of iatrogenic @entity11044 . It is a rapid, effective and minimally invasive technique that should be considered if @entity409 does not resolve spontaneously.

Transvaginal urethrolysis for @entity11044 after anti- XXXX surgery.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['incomplete bladder emptying'] @entity409 :: ('MESH:D008107', 'Disease') :: ['voiding dysfunction'] @entity11044 :: ('MESH:D014524', 'Disease') :: ['urethral obstruction', 'Urethral obstruction'] @entity3142 :: ('MESH:D014550', 'Disease') :: ['stress incontinence']
@entity322 :: (MESH:D014549,Disease) :: ['incontinence']
